News

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.
Mirage News5h
Zepbound Outduels Wegovy In Weight-loss Clinical Trial
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...
Patients Are Left With Few Options as GLP-1 Copycats Disappear
With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...